Recent research have centered on the intersection of glucagon-like peptide-1|GIP|GCGR stimulant therapies and dopamine communication. While GCGR agonists are widely employed for treating type 2 T2DM, their emerging consequences on reward circuits, specifically influenced by dopamine systems, are